Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity

(2013) S. M. Offer et al.   CANCER RESEARCH

Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients

(2011) S. Afzal et al.   CLINICAL CANCER RESEARCH

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

(2011) D. Caronia et al.   CLINICAL CANCER RESEARCH

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis

(2010) R Zarate et al.   BRITISH JOURNAL OF CANCER

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

(2010) E Martinez-Balibrea et al.   BRITISH JOURNAL OF CANCER

Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741

(2010) Howard L. McLeod et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05

(2010) Valérie Boige et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

(2010) B Glimelius et al.   PHARMACOGENOMICS JOURNAL

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

(2009) S. Afzal et al.   ANNALS OF ONCOLOGY

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

(2009) W Chua et al.   BRITISH JOURNAL OF CANCER

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer

(2009) M Gusella et al.   BRITISH JOURNAL OF CANCER

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients

(2009) Marie-Christine Etienne-Grimaldi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Study of the MTHFR Gene Polymorphism C677T in Colorectal Cancer

(2009) Kristoffer Derwinger et al.   Clinical Colorectal Cancer

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial

(2009) Michael S. Braun et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

(2009) Eray Goekkurt et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes

(2009) M. Wasif Saif et al.   JNCI-Journal of the National Cancer Institute

Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients

(2008) R. Sharma et al.   CLINICAL CANCER RESEARCH

A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression

(2008) N. Ribelles et al.   CURRENT DRUG METABOLISM

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer

(2008) Eva Martinez-Balibrea et al.   EUROPEAN JOURNAL OF CANCER

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients

(2008) Eva Gross et al.   PLoS One